UCB and Biogen's Dapirolizumab Pegol Shows Promise in Phase III SLE Study
CompanyDrug

UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study

Beijing Balance Medical Technology's ePTFE Implant Accepted for NMPA Review
CompanyMedical Device

Beijing Balance Medical Technology’s ePTFE Implant Accepted for NMPA Review

Betta Pharmaceuticals' MCLA-129 Approved for Clinical Trial in Advanced Solid Tumors
CompanyDrug

Betta Pharmaceuticals’ MCLA-129 Approved for Clinical Trial in Advanced Solid Tumors

Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
CompanyDeals

Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million

Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
CompanyDeals

Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins

Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe
CompanyDrug

Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe

LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
CompanyDeals

LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China

Worg Pharmaceuticals Secures Major Financing for Allergy and Autoimmune Disease Therapies
CompanyDeals

Worg Pharmaceuticals Secures Major Financing for Allergy and Autoimmune Disease Therapies

Abbott Laboratories Expands Global Diabetes Care with New Kilkenny Facility
Company

Abbott Laboratories Expands Global Diabetes Care with New Kilkenny Facility

AbbVie's Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
CompanyMedical Device

AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment

Rona Therapeutics' RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions
CompanyDrug

Rona Therapeutics’ RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions

Eli Lilly's Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study
CompanyDrug

Eli Lilly’s Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study